Finally, Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT‐AF) evaluated IL‐1β blockade with canakinumab versus placebo in 24 patients with persistent AF and baseline CRP >1.25 mg/dL undergoing external electrical cardioversion (ECV). The gene discussed is CRP; the disease is atrial fibrillation.